Jump to content
Powered by

Latest news

Here you can find the latest articles about the Baden-Württemberg healthcare industry.

  • Imaging Methods - 03/11/2016

    An international team of researchers is developing an MRI-based method for the early detection of human brain tumours. The method is called CEST-MRI and it detects elevated glucose concentrations in humour tissues, quantitatively and at high spatial resolution. It does not expose patients to radiation, is non-invasive and relatively inexpensive.

  • Article - 26/10/2016

    Gene therapy approaches are increasingly being used for treating life-threatening diseases in humans. GeneWerk GmbH, a spin-off of the DKFZ and the NCT in Heidelberg, offers customised, high-resolution molecular and bioinformatic analyses that ensure the efficacy and safety of gene therapy and immunotherapy studies.

  • High-tech - 20/10/2016

    The digitalisation of industry affects the entire value chain. From individual products to digitising workflows in companies and connecting companies with clients and service providers via the Internet of Things – Industry 4.0 makes completely new manufacturing processes possible and requires new and specific business models.

  • Article - 10/10/2016

    Teva is investing heavily in its biotechnological production site in Ulm. On behalf of BIOPRO Baden-Württemberg, Walter Pytlik spoke with Dr. Hermann Allgaier, CEO of Teva Biotech, about the importance of biotechnology for the Group and about Teva in general. The company is headquartered in Israel.

  • Article - 04/10/2016

    In cooperation with the University of Mainz, the Springer publishing house is now offering distance learning courses for laboratory and technical assistants who wish to study while they are working. The courses lead to a Bachelor of Science degree. The successful programme for ambitious non-academics is being developed in several Baden-Württemberg cities.

  • Article - 26/09/2016

    The University of Tübingen is optimising its drug development pipeline. The TuCADD consortium provides professional help to people who want to take potential drug candidates to clinical application. The coaching involves assistance with the entire phase I drug development phase from industry experts.

  • Article - 20/09/2016

    Since 2012, a DFG-funded research group called FOR1680 has been studying CRISPR-Cas, an immune system that unicellular bacteria and arachaea use to protect themselves against attacks from viruses and plasmids. Prof. Dr. Anita Marchfelder, a molecular biologist at Ulm University and coordinator of the FOR1680 research group, and many other researchers were surprised to find that prokaryotes incorporate the genetic material of enemies as a kind of…

  • Article - 13/09/2016

    Pharmaceutical and biotechnology companies are working intensively on the discovery and development of new drugs for the efficient and safe treatment of diseases. However, before drugs are authorised for treating humans and animals, they have to be made into a form that is acceptable. That is where a company called Catalent Pharma Solutions, with a facility in Schorndorf in the south of Germany, comes in.

  • Article - 12/09/2016

    Hepatocellular carcinoma is the second most common cause of cancer deaths worldwide. If the tumour is at an advanced stage, doctors have few treatment options. Researchers led by Prof. Dr. Lars Zender from the University of Tübingen have now identified one of the cancer's Achilles' heels, namely, the interaction between C-MYC and AURKA proteins, which can be destabilised with a drug, thus killing cancer cells.

  • Article - 08/09/2016

    DNA sequencing techniques have been developed along the lines of faster, further, cheaper. State-of-the-art methods make it possible to handle large projects in a relatively short period of time. However, the error rate is still very high. Dr. Maria Fyta and her team at the Institute for Computational Physics at the University of Stuttgart have carried out quantum-transport calculations which suggested that specific chemical modifications in the…

  • Article - 05/09/2016

    Apogenix AG, a biopharmaceutical company from Heidelberg that specialises in immuno-oncology, develops protein drugs that target central signalling pathways involved in regulating the growth, migration and apoptosis of malfunctioning cells and thus offer novel treatment options for cancer and other malignant diseases.

  • Article - 01/09/2016

    Scientists have developed a biotechnological process to produce bacterial alginate. The alginate quality is highly reproducible, making it suitable for the production of fibre-based medicinal products such as wound dressings.

Website address: https://www.gesundheitsindustrie-bw.de/en/article/news